WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today reported fourth-quarter and full-year 2011 financial results, including revenue from its first commercial product, JakafiTM, which was approved by the US Food & Drug Administration (FDA) for intermediate or high-risk myelofibrosis (MF) on November 16, 2011. The Company also provided 2012 financial guidance; described key Phase III data presented at the 2011 American Society of Hematology (ASH) Annual Meeting; and provided updated information about key clinical programs.
